FI112942B3 - Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi - Google Patents

Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi

Info

Publication number
FI112942B3
FI112942B3 FI920749A FI920749A FI112942B3 FI 112942 B3 FI112942 B3 FI 112942B3 FI 920749 A FI920749 A FI 920749A FI 920749 A FI920749 A FI 920749A FI 112942 B3 FI112942 B3 FI 112942B3
Authority
FI
Finland
Prior art keywords
alkyl
aryl
alkoxy
substd
halo
Prior art date
Application number
FI920749A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI920749A0 (fi
FI920749A7 (fi
FI112942B (fi
Inventor
Hiroaki Yanagisawa
Yasuo Shimoji
Koichi Fujimoto
Takuro Kanazaki
Yoshiya Amemiya
Hiroyuki Koike
Toshio Sada
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27549327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112942(B3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of FI920749A0 publication Critical patent/FI920749A0/fi
Publication of FI920749A7 publication Critical patent/FI920749A7/fi
Priority to FI955248A priority Critical patent/FI112941B/fi
Publication of FI112942B publication Critical patent/FI112942B/fi
Application granted granted Critical
Publication of FI112942B3 publication Critical patent/FI112942B3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI920749A 1991-02-21 1992-02-20 Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi FI112942B3 (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI955248A FI112941B (fi) 1991-02-21 1995-11-02 Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1'-bifenyylijohdannaisten valmistamiseksi

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
JP2709891 1991-02-21
JP2709891 1991-02-21
JP9658891 1991-04-26
JP9658891 1991-04-26
JP13488991 1991-06-06
JP13488991 1991-06-06
JP16713891 1991-07-08
JP16713891 1991-07-08
JP17397291 1991-07-15
JP17397291 1991-07-15
JP18484191 1991-07-24
JP18484191 1991-07-24

Publications (4)

Publication Number Publication Date
FI920749A0 FI920749A0 (fi) 1992-02-20
FI920749A7 FI920749A7 (fi) 1992-08-22
FI112942B FI112942B (fi) 2004-02-13
FI112942B3 true FI112942B3 (fi) 2012-03-13

Family

ID=27549327

Family Applications (2)

Application Number Title Priority Date Filing Date
FI920749A FI112942B3 (fi) 1991-02-21 1992-02-20 Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi
FI955248A FI112941B (fi) 1991-02-21 1995-11-02 Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1'-bifenyylijohdannaisten valmistamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI955248A FI112941B (fi) 1991-02-21 1995-11-02 Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1'-bifenyylijohdannaisten valmistamiseksi

Country Status (22)

Country Link
EP (2) EP0503785B3 (cs)
JP (1) JPH07121918B2 (cs)
KR (1) KR0128289B1 (cs)
CN (3) CN1045770C (cs)
AT (2) ATE200777T1 (cs)
CA (2) CA2229000C (cs)
CZ (1) CZ289194B6 (cs)
DE (6) DE10299043I2 (cs)
DK (2) DK0503785T3 (cs)
ES (2) ES2156866T3 (cs)
FI (2) FI112942B3 (cs)
GR (2) GR3035906T3 (cs)
HU (3) HU223338B1 (cs)
IE (1) IE920540A1 (cs)
IL (3) IL101034A (cs)
IS (1) IS1756B (cs)
LU (4) LU91056I2 (cs)
NL (3) NL300133I2 (cs)
NO (6) NO304516B3 (cs)
NZ (1) NZ241681A (cs)
PT (2) PT545912E (cs)
RU (1) RU2128173C1 (cs)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
EP0573218B1 (en) * 1992-06-02 2001-03-07 Sankyo Company Limited 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use
TW259786B (cs) * 1992-12-17 1995-10-11 Sankyo Co
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
RU2123847C1 (ru) * 1994-03-16 1998-12-27 Санкио Компани Лимитед Лекарственное средство и способ лечения повышенного глазного давления и/или глаукомы
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AUPN786896A0 (en) 1996-02-02 1996-02-29 Telstra Corporation Limited A network fault system
CZ299162B6 (cs) 1996-07-15 2008-05-07 Sankyo Company, Limited Farmaceutický prípravek a souprava
AU5576498A (en) * 1997-02-05 1998-08-26 Sankyo Company Limited Prophylactic or therapeutic agent for diabetic complication
USD441509S1 (en) 1997-08-25 2001-05-01 Mastrad S.A. Combined hand cleaner and hand cleaner base
AU141230S (en) 1999-02-26 2000-07-25 Unilever Plc Detergent tablet
EP1193258A4 (en) 1999-06-22 2002-11-13 Takeda Chemical Industries Ltd PROCESS FOR THE PREPARATION OF IMIDAZOLE DERIVATIVES
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4521844B2 (ja) * 2000-04-18 2010-08-11 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
CA2420844A1 (en) * 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
ES2262689T3 (es) * 2000-11-21 2006-12-01 Sankyo Company, Limited Composicion que contiene un antagonista del receptor de angiotensina ii y un diuretico y su uso para el tratamiento de la hipertension.
WO2003020315A1 (fr) * 2001-08-28 2003-03-13 Sankyo Company, Limited Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii
CA2514921C (en) 2003-01-31 2013-04-30 Sankyo Company, Limited Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension
CN1197866C (zh) * 2003-03-21 2005-04-20 上海医药工业研究院 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法
JP4489020B2 (ja) 2003-04-15 2010-06-23 第一三共株式会社 眼内血管新生性疾患の予防又は治療のための医薬
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7692023B2 (en) 2004-02-11 2010-04-06 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
KR20070006774A (ko) 2004-03-17 2007-01-11 노파르티스 아게 치료에서 레닌 억제제의 용도
EP1706401A1 (en) * 2004-09-02 2006-10-04 Teva Pharmaceutical Industries Ltd. Preparation of olmesartan medoxomil
CA2580862A1 (en) 2004-10-08 2006-04-20 Novartis Ag Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
KR101021828B1 (ko) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
MX2007007303A (es) * 2004-12-30 2007-07-18 Teva Pharma Proceso para preparar olmesartan medoxomil a ph superior a 2,5.
WO2006073519A1 (en) * 2005-01-03 2006-07-13 Teva Pharmaceutical Industries Ltd. Olmesartan medoxomil with reduced levels of impurities
DE602006010364D1 (de) * 2005-04-22 2009-12-24 Daiichi Sankyo Co Ltd Pharmazeutikum zur prävention oder behandlung von metabolischer knochenkrankheit
EP1816131A1 (en) * 2006-02-06 2007-08-08 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of olmesartan medoxomil
EA014026B1 (ru) * 2005-07-29 2010-08-30 Крка, Товарна Здравил, Д.Д., Ново Место Способ получения олмесартан медоксомила
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
CZ299902B6 (cs) * 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
EP1801111B1 (en) * 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Novel polymorph forms of olmesartan medoxomil
US20090012132A1 (en) * 2006-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Pharmaceutical Package
ATE526963T1 (de) 2006-05-04 2011-10-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit olmesartan- medoxomil
WO2007148344A2 (en) * 2006-06-19 2007-12-27 Matrix Laboratories Limited Process for the preparation of olmesartan medoxomil
WO2008096829A1 (ja) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. ３環系化合物
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
CN101679390A (zh) * 2007-03-23 2010-03-24 第一三共株式会社 奥美沙坦酯的粉碎结晶
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101311168B (zh) * 2007-05-21 2010-12-08 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
CN101311169B (zh) * 2007-05-21 2011-03-16 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0710680D0 (en) * 2007-06-05 2007-07-11 Generics Uk Ltd Novel crystalline form of olmesartan medoxmil
JP5311413B2 (ja) * 2007-06-22 2013-10-09 第一三共株式会社 アルツハイマー病の予防又は治療のための医薬
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN102083823B (zh) 2008-06-09 2015-10-07 第一三共株式会社 1-联苯甲基咪唑化合物的制备方法
WO2010016549A1 (ja) 2008-08-06 2010-02-11 協和発酵キリン株式会社 ３環系化合物
WO2010054515A1 (zh) 2008-11-17 2010-05-20 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
JP2009102340A (ja) * 2008-12-04 2009-05-14 Daiichi Sankyo Co Ltd イミダゾール誘導体の製造法（２）
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
CN102414201B (zh) 2009-04-28 2015-10-14 第一三共株式会社 溶剂化物晶体
CN102414200B (zh) 2009-04-28 2014-12-17 第一三共株式会社 奥美沙坦酯的制备方法
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
CN102050816A (zh) * 2009-10-28 2011-05-11 北京万全阳光医学技术有限公司 一种合成奥美沙坦酯的方法
HUP0900788A2 (en) 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
CA2785920A1 (en) 2010-01-05 2011-07-14 Ratiopharm Gmbh Solid oral dosage form containing olmesartan medoxomil
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
EA022420B1 (ru) 2010-03-10 2015-12-30 Пробиодруг Аг Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
JP5137996B2 (ja) * 2010-04-28 2013-02-06 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102060778B (zh) * 2010-12-24 2012-05-23 江苏江神药物化学有限公司 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法
CN102206208A (zh) * 2010-12-24 2011-10-05 上海现代制药股份有限公司 含低水平杂质的奥美沙坦酯的制备方法
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2013018899A1 (ja) 2011-08-03 2013-02-07 協和発酵キリン株式会社 ジベンゾオキセピン誘導体
US20130158080A1 (en) 2011-12-15 2013-06-20 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating hypertension in black patients
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
CN104583185A (zh) 2012-08-31 2015-04-29 株式会社Api 联芳基化合物的制造方法
IN2015DN02241A (cs) 2012-09-26 2015-08-21 Api Corp
WO2014054798A1 (ja) 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN103012382B (zh) * 2012-12-05 2016-10-05 迪沙药业集团有限公司 一种奥美沙坦酯的制备方法
CN103044407A (zh) * 2012-12-20 2013-04-17 安徽悦康凯悦制药有限公司 奥美沙坦酯的制备方法
CN103965167A (zh) * 2013-01-29 2014-08-06 通化济达医药有限公司 咪唑羧酸衍生物
JP2014152127A (ja) * 2013-02-06 2014-08-25 Tokuyama Corp オルメサルタンメドキソミルの製造方法
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015012205A1 (ja) 2013-07-23 2015-01-29 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN103880825B (zh) * 2014-03-14 2019-03-05 浙江华海药业股份有限公司 一种高纯的三苯甲基奥美沙坦酯的制备工艺
CN104356069B (zh) * 2014-11-18 2016-09-14 黄冈鲁班药业有限公司 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用
CN104447564B (zh) * 2014-11-24 2016-08-31 广州天赐高新材料股份有限公司 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法
CN104402873A (zh) * 2014-12-02 2015-03-11 千辉药业（安徽）有限责任公司 一种奥美沙坦酯中间体的制备方法
CN105481842A (zh) * 2015-12-15 2016-04-13 江苏中邦制药有限公司 一种奥美沙坦酯的制备方法
JP6934859B2 (ja) 2016-03-24 2021-09-15 第一三共株式会社 腎疾患の治療のための医薬
CN106749195A (zh) * 2016-12-30 2017-05-31 青岛黄海制药有限责任公司 一种奥美沙坦酯中间体杂质合成、鉴定的方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN109081812B (zh) * 2018-08-30 2022-08-16 黄冈鲁班药业股份有限公司 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
CN112778209B (zh) * 2019-11-04 2024-05-14 宜昌东阳光长江药业股份有限公司 一种二酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4916129A (en) 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
CA2016710A1 (en) 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
EP0515548A4 (en) * 1990-02-13 1993-03-10 Merck & Co. Inc. Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
HU9200578D0 (en) 1992-05-28
DE122009000024I1 (de) 2009-09-17
CZ51692A3 (en) 1993-03-17
EP0503785A1 (en) 1992-09-16
IL101034A (en) 1996-10-16
NO2011013I1 (no) 2011-08-22
PT503785E (pt) 2001-08-30
CA2061607A1 (en) 1992-08-22
EP0545912B1 (en) 2001-04-25
EP0545912A3 (en) 1993-06-16
FI920749A0 (fi) 1992-02-20
NO304516B1 (no) 1999-01-04
ES2156866T3 (es) 2001-08-01
GR3035909T3 (en) 2001-08-31
RU95101430A (ru) 1997-02-20
DE122005000051I1 (de) 2006-01-26
LU91056I2 (fr) 2004-10-19
NL300375I1 (nl) 2009-04-01
DE69231801T2 (de) 2001-12-06
GR3035906T3 (en) 2001-08-31
PT545912E (pt) 2001-08-30
DE69231798D1 (de) 2001-05-31
KR0128289B1 (ko) 1998-04-02
CN1065063A (zh) 1992-10-07
LU91847I2 (fr) 2011-09-26
RU2128173C1 (ru) 1999-03-27
KR920016429A (ko) 1992-09-24
DK0503785T3 (da) 2001-06-18
NL300133I1 (nl) 2003-10-01
FI955248A7 (fi) 1995-11-02
NO2006012I1 (no) 2006-10-30
DE10299043I2 (de) 2003-08-07
EP0503785B1 (en) 2001-04-25
HUT60475A (en) 1992-09-28
NO954507L (no) 1992-08-24
DE10299043I1 (de) 2003-03-27
FI112941B (fi) 2004-02-13
CA2229000A1 (en) 1992-08-22
IL101034A0 (en) 1992-11-15
CA2061607C (en) 1999-01-19
CN1188645A (zh) 1998-07-29
HU211934A9 (en) 1996-01-29
IE920540A1 (en) 1992-08-26
ATE200778T1 (de) 2001-05-15
JPH07121918B2 (ja) 1995-12-25
NO920688L (no) 1992-08-24
ATE200777T1 (de) 2001-05-15
HU223338B1 (hu) 2004-06-28
ES2157895T7 (es) 2012-06-14
CZ289194B6 (cs) 2001-11-14
CA2229000C (en) 2002-04-09
NO304516B3 (no) 2012-06-11
NO954507D0 (no) 1995-11-09
CN1189490A (zh) 1998-08-05
HU9601179D0 (en) 1996-07-29
NO2009019I1 (no) 2009-09-21
AU647887B2 (en) 1994-03-31
IE970752A1 (en) 2000-02-23
JPH0578328A (ja) 1993-03-30
DE69231801D1 (de) 2001-05-31
FI920749A7 (fi) 1992-08-22
DK0545912T3 (da) 2001-06-18
EP0545912A2 (en) 1993-06-09
IS1756B (is) 2000-12-28
CN1101384C (zh) 2003-02-12
HU223667B1 (hu) 2004-11-29
ES2157895T3 (es) 2001-09-01
DE122011000011I1 (de) 2011-06-16
NO920688D0 (no) 1992-02-21
NO2003009I2 (en) 2007-12-11
IS3819A (is) 1992-08-22
CN1121859C (zh) 2003-09-24
IL114996A0 (en) 1995-12-08
IL114996A (en) 1997-07-13
NL300133I2 (nl) 2004-03-01
FI112942B (fi) 2004-02-13
HK1011361A1 (en) 1999-07-09
EP0503785B3 (en) 2012-02-29
HK1011969A1 (en) 1999-07-23
AU1112592A (en) 1992-08-27
CN1045770C (zh) 1999-10-20
LU91571I2 (fr) 2009-07-13
NL300227I1 (nl) 2006-06-01
DE69231798T2 (de) 2001-12-06
NZ241681A (en) 1993-07-27
LU91330I2 (fr) 2007-06-04
DE69231798T3 (de) 2012-07-12
NO304517B1 (no) 1999-01-04
FI955248A0 (fi) 1995-11-02

Similar Documents

Publication Publication Date Title
FI112942B3 (fi) Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
PT91435A (pt) Processo para a preparacao de aril-alquil-aminas e -amidas possuindo propriedades anticonvulsivas e neuroprotectoras e de composicoes farmaceuticas que as contem
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
AR010808A1 (es) Uso de un compuesto para la fabricacion de un medicamento util para tratar o inhibir neutropenia y/o para acelerar la recuperacion de neutrofilos y unacomposicion farmaceutica
HUT60742A (en) Method for producing imidqzo-benzodiazepine-2-(1h)-one derivatives and pharmaceutical preparatives containing them

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20040002

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20060012

PC Transfer of assignment of patent

Owner name: DAIICHI SANKYO COMPANY LIMITED

Free format text: DAIICHI SANKYO COMPANY LIMITED

SPCG Supplementary protection certificate granted
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: C20110023

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 328

Extension date: 20170220

MA Patent expired